Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity

Interferon-α (IFNα) has been prescribed to effectively treat multiple myeloma (MM) and other malignancies for decades. Its use has waned in recent years, however, due to significant toxicity and a narrow therapeutic index (TI). We sought to improve IFNα’s TI by, first, attaching it to an anti-CD38 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pogue, Sarah L., Taura, Tetsuya, Bi, Mingying, Yun, Yong, Sho, Angela, Mikesell, Glen, Behrens, Collette, Sokolovsky, Maya, Hallak, Hussein, Rosenstock, Moti, Sanchez, Eric, Chen, Haiming, Berenson, James, Doyle, Anthony, Nock, Steffen, Wilson, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017640/
https://www.ncbi.nlm.nih.gov/pubmed/27611189
http://dx.doi.org/10.1371/journal.pone.0162472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017640/
https://www.ncbi.nlm.nih.gov/pubmed/27611189
http://dx.doi.org/10.1371/journal.pone.0162472

Ejemplares similares